latimes.com/news/nation-and-world/la-na-health-senate11-2009dec11,0,1002684.story
latimes.com
Senate health debate hits snag over imported drugs
The idea of expanding access to lower-cost prescription medicines from
overseas has broad support, but opposition from the U.S. drug industry could
endanger the healthcare overhaul.
By Janet Hook and Tom Hamburger
December 11, 2009
Reporting from Washington
Expanding access to low-cost prescription drugs from overseas might look like
a sure winner in the effort to make healthcare more affordable. President Obama
supports the idea, as do many Democrats and several Republicans.
But the
seemingly popular proposal brought the Senate healthcare debate to a standstill
Thursday, as Democrats divided over whether they should bow to the drug
industry's fierce opposition.
Majority Leader Harry Reid (D-Nev.)
temporarily halted consideration of the healthcare bill after three days of
inconclusive debate on an amendment by Sens. Byron L. Dorgan (D-N.D.) and John
McCain (R-Ariz.). The provision would allow pharmacies and wholesalers to import
drugs from countries with safety standards comparable to
America's.
Despite Obama's support for importation, the White House fears
that if the amendment is approved, the drug industry will oppose the
bill.
Industry support is considered a key to passage. That is why the
White House negotiated a controversial deal to limit the financial effect of the
overhaul on the industry in exchange for its support.
The drug-import
amendment was not part of that negotiation, but it was widely believed that the
industry would oppose the bill if such an amendment were included. Around the
time of the negotiations, the White House issued a statement saying that
importation legislation would not be necessary if a healthcare overhaul were
enacted, because the overhaul would result in generally lower
costs.
Earlier this week, the Food and Drug Administration announced in a
letter that it opposed Dorgan's amendment because it would be "logistically
challenging" to implement and raised "significant" concerns about drug
safety.
Democrats from states with major drug companies strongly oppose
the amendment. One of them, Sen. Frank R. Lautenberg (D-N.J.), offered an
alternative to address the safety concerns.
In the past, supporters of
easier importation have seen similar amendments as "poison pills" -- effectively
neutering the proposal by requiring U.S. officials to certify in advance that
imported drugs would be safe and effective.
The George W. Bush
administration also cited safety issues in opposing importation.
Even as
the prescription-drug debate brewed Thursday, Democratic leaders tried to build
momentum behind the tentative compromise on a more central problem: the dispute
over a government insurance plan.
House Speaker Nancy Pelosi (D-San
Francisco) expressed support for a key element of the deal that would allow
Americans buy into Medicare beginning at age 55. Speaking to reporters, she did
not repeat her demand that a new government-run plan be part of the final
legislation.
Pelosi also raised the prospect that she would bring the
House back into session during Christmas week if the Senate passed its bill by
then.
Senate Democrats are waiting for the nonpartisan Congressional
Budget Office to report the potential cost of the compromise, probably by early
next week.
Advocates of the drug-import amendment say that it would
generate $100 billion in savings to the government and a windfall for consumers
who have faced climbing prescription drug prices in recent years.
The
resistance from his own party infuriated Dorgan, as did Lautenberg's amendment.
"It is an amendment designed to kill our effort to allow the reimportation of
drugs and put the brakes on skyrocketing drug prices," he said.
The White
House issued formal statements saying that the president backs the concept of
importation -- but has concerns about its safety.
"The president supports
reimportation of safe and effective drugs," said White House spokeswoman Linda
Douglass. "The Food and Drug Administration has raised safety concerns about the
current proposal and will continue exploring policy options to create a pathway
to importing safe and effective drugs."
janet.hook@latimes.com
tom.hamburger@latimes.com
Noam
N. Levey in the Washington bureau contributed to this report.
Copyright © 2009, The Los Angeles Times